{"title":"慢性髓系白血病治疗策略的最新进展","authors":"N. Hamed","doi":"10.19080/CTOIJ.2020.16.555949","DOIUrl":null,"url":null,"abstract":"The goal of CML treatment in the recent era is to discontinue medication for treatment free remission after achieving a stable deep molecular response. A prerequisite for TKI discontinuation is the assessment of the remaining tumor load by standardized molecular monitoring using high quality quantitative PCR by the international scale. Molecular monitoring post-treatment suspension is also imperative for CML patients attempting TFR.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"174 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Update in Management Strategies of Chronic Myeloid Leukemia\",\"authors\":\"N. Hamed\",\"doi\":\"10.19080/CTOIJ.2020.16.555949\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The goal of CML treatment in the recent era is to discontinue medication for treatment free remission after achieving a stable deep molecular response. A prerequisite for TKI discontinuation is the assessment of the remaining tumor load by standardized molecular monitoring using high quality quantitative PCR by the international scale. Molecular monitoring post-treatment suspension is also imperative for CML patients attempting TFR.\",\"PeriodicalId\":9575,\"journal\":{\"name\":\"Cancer Therapy & Oncology International Journal\",\"volume\":\"174 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Therapy & Oncology International Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.19080/CTOIJ.2020.16.555949\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Therapy & Oncology International Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19080/CTOIJ.2020.16.555949","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Update in Management Strategies of Chronic Myeloid Leukemia
The goal of CML treatment in the recent era is to discontinue medication for treatment free remission after achieving a stable deep molecular response. A prerequisite for TKI discontinuation is the assessment of the remaining tumor load by standardized molecular monitoring using high quality quantitative PCR by the international scale. Molecular monitoring post-treatment suspension is also imperative for CML patients attempting TFR.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
